C-Reactive Protein Predicts Progression of Peripheral Arterial Disease in Patients with Type 2 Diabetes: A 5-Year Follow-Up Study

Open access


Background: Previous studies have indicated that high sensitivity C-reactive protein (hs-CRP) is a risk factor for the peripheral arterial disease (PAD) in diabetes. This study aimed to evaluate the possible predictive significance of hs-CRP for the development and progression of PAD in patients with type 2 diabetes (T2D).

Methods: The study included 80 patients previously diagnosed with T2D, aged 45–70 years, divided into group A (T2D patients with PAD; n=38) and group B (T2D patients without PAD; n=42). After five years, all the patients were re-examined and divided into subgroups depending on de novo development of PAD or progression of previously diagnosed PAD. Ankle-Brachial Index (ABI) measurement was used for PAD diagnosis and hs-CRP was determined by nephelometry.

Results: We found significantly higher hs-CRP levels in group A compared to group B, but only at baseline. Among the patients in group A, those with later progression of PAD (subgroup A1) had the highest levels of hs-CRP at baseline, although not significantly different from those in subgroup A2 (non-progressors). In contrast, hs-CRP level was significantly higher in subgroup B1 (progressors) in comparison to subgroup B2 (non-progressors) at both the first and second exam. Of all the investigated metabolic parameters, hs-CRP was the only independent predictor of PAD progression (OR=0.456, 95% CI=0.267–0.7815, p=0.004). The cut-off point for hs-CRP was 2.5 mg/L (specificity 75% and sensitivity 73.3%) with the relative risk for PAD of 2.93 (95% CI=1.351–6.3629).

Conclusions: Our study implies that hs-CRP can be used as a reliable predictor for the progression of PAD in patients with T2D.

1. Willerson J T, Cohn JN, Wellens HJJ, Holmes DR Jr, eds. Cardiovascular Medicine 2. London: Springer 2007; 1681–703.

2. Marso S P, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 2006; 47(5): 921–9.

3. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in general population. Int J Epidemiol 1996; 25: 1172–81.

4. Diehm C, Allenberg JR, Pittrow D, et al; German Epidemiological Trial on Ankle Brachial Index Study Group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120: 2053–61.

5. Murabito JM, D'Agostino RB, Silbershatz H, Wilson W F. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation 1997; 96: 44–9.

6. The PARTNERS program: A national survey of peripheral arterial disease detection, awareness, and treatment. JAMA 2001; 286: 1317–24.

7. Prevalence of and risk factors for peripheral arterial disease in the United States. Results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004; 110: 738–43.

8. Makin A, Lip GYH, Silverman S, Beevers DG. Peripheral vascular disease and hypertension: a forgotten association? J Hum Hypertens 2001; 15: 447–54.

9. Britton KA, Mukamal KJ, Ix JH, Siscovick DS, Newman AB, de Boer IH, Thacker EL, Biggs ML, et al. Insulin re sis tan ce and incident peripheral arterial disease in the Car dio-vascular Health Study. Vasc Med 2012; 17: 85–93.

10. Pande RL, Perlstein TS, Beckman JA, Creader MA. Association of insulin resistance and inflammation with peripheral arterial disease The National Health and Nutrition Examination Survey, 1999 to 2004. Circulation 2008; 118: 33–41.

11. Nilsson J. CRP – maker or marker of cardiovascular disease? Art Thromb Vasc Biol 2005; 25: 1527–8.

12. Williams JR. The Declaration of Helsinki and public health. B World Health Organ 2008; 86: 650–1.

13. Eknoyan G. Adolphe Quetelet (1796–1874) – the average man and indices of obesity. Nephrol Dial Transplant 2008; 23: 47–51.

14. Romero-Coral A, Somers VK, Sierra-Johnson J, Thomas RJ, et al. Accuracy of body mass index in diagnosing obesity in adult general population. Int J Obesity 2008; 32: 956–9.

15. National Institute of Diabetes and Digestive and Kidney Disease. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. NIH Publication 2000; 00–4084: 7–23.

16. 2013 ESH/ESC Guidelines for management of arterial hypertension. The Task Force for management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.

17. Hull SK, Kishman CR Jr. What is the best test for peripheral vascular disease? J Fam Practice 2008; 57: 403–5.

18. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadl Y Y, Fortman S P, Hong Y, Myers GL, et al, for the Centres for Disease Control and Prevention and the American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for health care professionals from the Centres for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511.

19. Matthews DR, Hosker J P, Rudenski AS, Naylor BA, Treacher D F, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412–9.

20. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–95.

21. Haffner MS, Kennedy E, Gonzales C, et al. A prospective analysis of the HOMA Model: The Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138–41.

22. Haffner MS, Miettienen H, Stern PM. The Homeostasis Model in San Antonio Heart Study. Diabetes Care 1997; 20: 1087–97.

23. Campbell MJ, Swinscow TDV, eds. Statistics at Square One 2002. London: Wiley-Blackwell, BMJ Books; 2002. pp. 111–145.

24. Wallenstein S, Witters J. The power of Mantel-Haenszel test for grouped failure time date. Biometrics 1993; 49: 1077–97.

25. Signorelli SS, Fiore V, Malaponte G. Inflammation and peripheral arterial disease: The value of circulating bio-markers. Int J Mol Med 2014; 33; 777–83.

26. Vainas T, Stassen F, de Graff R, et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg 2005; 42: 243–51.

27. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283–94.

28. Hozawa A, Ohmori K, Kuriyama S, Shimazu T, Niu K, Watando A, et al. C-reactive protein and peripheral arterial disease among Japanese elderly: the Tsurugaya Project. Hypertens Res 2004; 27: 955–61.

29. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132–40.

30. Ridker PM. High-sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–8.

31. Korita I, Bulo A, Langlois, Blaton V. Inflammation markers in patients with cardiovascular disease and metabolic syndrome. J Med Biochem 2013; 32: 214–9.

32. Ridker PM, Cushman M, Stampfler MJ, Hennekens CH. Plasma Concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425–8.

33. Goldhaber SZ. European Atherosclerosis Society Screening Recommendations for lipoprotein (a) and High-Sensitivity C-Reactive Protein: Double Standard or Failure of Evidence-Based Medicine. Clinical Chemistry 2009; 55: 378–84.

34. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113: 2623–9.

35. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley C V, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384–92.

36. Van der Meer IM, Oei H-HS, Hofman A, Pols HAP, de Jong FH, Witteman JCM. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extra-coronary atherosclerosis: The Rotterdam Coronary Calcification Study. Atherosclerosis 2006; 189: 464–89.

37. McDermott MM, Guralnik JM, Greenland P, Green D, Liu K, Ridker PM, Chan C, et al. Inflammatory and throm-botic blood markers and walking-related disability in men and women with and without peripheral arterial disease. J Am Geriatr Soc 2004; 52: 1888–94.

38. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003; 107: 3191–8.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information

IMPACT FACTOR 2018: 2,000
5-year IMPACT FACTOR: 1,075

CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 236 187 6
PDF Downloads 99 81 8